Maintenance psoralen plus ultraviolet a therapy: Does it have a role in the treatment of severe atopic eczema? [2]

British Journal of Dermatology

Volumn 146, Issue 4, 2002, Pages 705-707

  Morris, Andrew D ^a   Saihan, E M ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BERGAPTEN; CYCLOSPORIN; METHOXSALEN; STEROID;

ADULT; AGED; ATOPIC DERMATITIS; CANCER RISK; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LENTIGO; LETTER; MAINTENANCE THERAPY; MALE; PATIENT SATISFACTION; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PRURITUS; PUVA; RELAPSE; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

EID: 0036237571     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.46862.x     Document Type: Letter

References (8)

1. Oral psoralen photochemotherapy of atopic eczema
2. The carcinogenic risk of treatments for severe psoriasis
3. And the PUVA Follow-up Study. The risk of melanoma in association with long-term exposure to PUVA
4. Guidelines for PUVA
5. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppression regimens
6. Cancers following cyclosporine therapy
7. The role of psoralen photochemotherapy (PUVA) in the treatment of severe atopic eczema in adolescents
8. Narrow-band (TL01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis